The origin and development of plaques and phosphorylated tau are associated with axonopathy in Alzheimer's disease.
Journal: 2012/February - Neuroscience Bulletin
ISSN: 1995-8218
Abstract:
OBJECTIVE
The production of neurotoxic β-amyloid and the formation of hyperphosphorylated tau are thought to be critical steps contributing to the neuropathological mechanisms in Alzheimer's disease (AD). However, there remains an argument as to their importance in the onset of AD. Recent studies have shown that axonopathy is considered as an early stage of AD. However, the exact relationship between axonopathy and the origin and development of classic neuropathological changes such as senile plaques (SPs) and neurofibrillary tangles (NFTs) is unclear. The present study aimed to investigate this relationship.
METHODS
Postmortem tracing, combined with the immunohistochemical or immunofluorescence staining, was used to detect axonopathy and the formation of SPs and NFTs.
RESULTS
Axonal leakage-a novel type of axonopathy, was usually accompanied with the extensive swollen axons and varicosities, and was associated with the origin and development of Aβ plaques and hyperphosphorylated tau in the brains of AD patients.
CONCLUSIONS
Axonopathy, particularly axonal leakage, might be a key event in the initiation of the neuropathological processes in AD.
Relations:
Content
Citations
(13)
References
(41)
Diseases
(1)
Conditions
(2)
Chemicals
(1)
Genes
(1)
Organisms
(1)
Processes
(1)
Anatomy
(6)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Neurosci Bull 27(5): 287

The origin and development of plaques and phosphorylated tau are associated with axonopathy in Alzheimer’s disease

Abstract

Objective

The production of neurotoxic β-amyloid and the formation of hyperphosphorylated tau are thought to be critical steps contributing to the neuropathological mechanisms in Alzheimer’s disease (AD). However, there remains an argument as to their importance in the onset of AD. Recent studies have shown that axonopathy is considered as an early stage of AD. However, the exact relationship between axonopathy and the origin and development of classic neuropathological changes such as senile plaques (SPs) and neurofibrillary tangles (NFTs) is unclear. The present study aimed to investigate this relationship.

Methods

Postmortem tracing, combined with the immunohistochemical or immunofluorescence staining, was used to detect axonopathy and the formation of SPs and NFTs.

Results

“Axonal leakage”-a novel type of axonopathy, was usually accompanied with the extensive swollen axons and varicosities, and was associated with the origin and development of Aβ plaques and hyperphosphorylated tau in the brains of AD patients.

Conclusion

Axonopathy, particularly axonal leakage, might be a key event in the initiation of the neuropathological processes in AD.

Keywords: Alzheimer’s disease, axonopathy, senile plaques, neurofibrillary tangles, postmortem tracing

摘要

目的

神经毒性β-淀粉样蛋白沉积和tau蛋白过度磷酸化是阿尔茨海默病(Alzheimer’s disease, AD)神经病理机制的两个关键阶段, 然而关于它们在启动AD病程的重要性上仍存在争议。 最近研究显示, 轴突病变发生于AD 的早期, 然而轴突病变与老年斑(senile plaques, SPs)和神经纤维缠结(neurofibrillary tangles, NFTs)的发生发展之间的确切关系仍不清楚, 本研究旨在揭示它们之间的联系。

方法

运用神经示踪技术结合免疫组织化学、 免疫组织化学和免疫荧光双标技术, 研究AD患者大脑中的轴突病变以及SPs和NFTs的形成情况。

结果

AD患者的脑组织中呈现出一种新形式的轴突病变—“轴突漏”, 并伴随有大量肿胀的轴突和膨体。 此外, 轴突漏与-淀粉样蛋白沉积和tau蛋白过度磷酸化的形成及发展有关。

结论

轴突病变尤其是“轴突漏”可能是起始AD神经病理进程的一个关键事件。

关键词: 阿尔茨海默病, 轴突病变, 老年斑, 神经纤维缠结, 离体示踪

Objective

The production of neurotoxic β-amyloid and the formation of hyperphosphorylated tau are thought to be critical steps contributing to the neuropathological mechanisms in Alzheimer’s disease (AD). However, there remains an argument as to their importance in the onset of AD. Recent studies have shown that axonopathy is considered as an early stage of AD. However, the exact relationship between axonopathy and the origin and development of classic neuropathological changes such as senile plaques (SPs) and neurofibrillary tangles (NFTs) is unclear. The present study aimed to investigate this relationship.

Methods

Postmortem tracing, combined with the immunohistochemical or immunofluorescence staining, was used to detect axonopathy and the formation of SPs and NFTs.

Results

“Axonal leakage”-a novel type of axonopathy, was usually accompanied with the extensive swollen axons and varicosities, and was associated with the origin and development of Aβ plaques and hyperphosphorylated tau in the brains of AD patients.

Conclusion

Axonopathy, particularly axonal leakage, might be a key event in the initiation of the neuropathological processes in AD.

目的

神经毒性β-淀粉样蛋白沉积和tau蛋白过度磷酸化是阿尔茨海默病(Alzheimer’s disease, AD)神经病理机制的两个关键阶段, 然而关于它们在启动AD病程的重要性上仍存在争议。 最近研究显示, 轴突病变发生于AD 的早期, 然而轴突病变与老年斑(senile plaques, SPs)和神经纤维缠结(neurofibrillary tangles, NFTs)的发生发展之间的确切关系仍不清楚, 本研究旨在揭示它们之间的联系。

方法

运用神经示踪技术结合免疫组织化学、 免疫组织化学和免疫荧光双标技术, 研究AD患者大脑中的轴突病变以及SPs和NFTs的形成情况。

结果

AD患者的脑组织中呈现出一种新形式的轴突病变—“轴突漏”, 并伴随有大量肿胀的轴突和膨体。 此外, 轴突漏与-淀粉样蛋白沉积和tau蛋白过度磷酸化的形成及发展有关。

结论

轴突病变尤其是“轴突漏”可能是起始AD神经病理进程的一个关键事件。

Wuhan Institute for Neuroscience and Neuroengineering, South-Central University for Nationalities, Wuhan, 430074 China
Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, Amsterdam, 1098XH the Netherlands
Department of Ultrapathology, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, 430030 China
Jia-Pei Dai, Phone: +86-27-67841165, Fax: +86-27-67840917, nc.ude.ceucs.liam@iadj.
Corresponding author.
Received 2011 Jul 17; Accepted 2011 Aug 20.

References

  • 1. Masliah E., Mallory M., Deerinck T., DeTeresa R., Lamont S., Miller A., et al Re-evaluation of the structural organization of neuritic plaques in Alzheimer’s disease. J Neuropathol Exp Neurol. 1993;52:619–632. doi: 10.1097/00005072-199311000-00009.] [[PubMed][Google Scholar]
  • 2. Goedert MTau protein and the neurofibrillary pathology of Alzheimer’s disease. Trends Neurosci. 1993;16:460–465. doi: 10.1016/0166-2236(93)90078-Z.] [[PubMed][Google Scholar]
  • 3. Hardy J., Allsop DAmyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci. 1991;12:383–388. doi: 10.1016/0165-6147(91)90609-V.] [[PubMed][Google Scholar]
  • 4. Armstrong R.A., Myers D., Smith C.U.MThe spatial patterns of plaques and tangles in Alzheimer’s disease do not support the ‘Cascade hypothesis’ Dementia. 1993;4:16–20.[PubMed][Google Scholar]
  • 5. Terry R.DThe pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol. 1996;55:1023–1025.[PubMed][Google Scholar]
  • 6. Neve R.L., Robakis N.KAlzheimer’s disease: a re-examination of the amyloid hypothesis. Trends Neurosci. 1998;21:15–19. doi: 10.1016/S0166-2236(97)01168-5.] [[PubMed][Google Scholar]
  • 7. Hardy J., Selkoe D.JThe amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356. doi: 10.1126/science.1072994.] [[PubMed][Google Scholar]
  • 8. Mudher A., Lovestone SAlzheimer’s disease-do tauists and bap tists finally shake hands? Trends Neurosci. 2002;25:22–26. doi: 10.1016/S0166-2236(00)02031-2.] [[PubMed][Google Scholar]
  • 9. Duyckaerts CLooking for the link between plaques and tangles. Neurobiol Aging. 2004;25:735–739. doi: 10.1016/j.neurobiolaging.2003.12.014.] [[PubMed][Google Scholar]
  • 10. Mattson M.PPathways towards and away from Alzheimer’s disease. Nature. 2004;430:631–639. doi: 10.1038/nature02621.] [[Google Scholar]
  • 11. Schönheit B., Zarski R., Ohm T.GSpatial and temporal relationships between plaques and tangles in Alzheimer-pathology. Neurobiol Aging. 2004;25:697–711. doi: 10.1016/j.neurobiolaging.2003.09.009.] [[PubMed][Google Scholar]
  • 12. Tanzi R.E., Bertram LTwenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545–555. doi: 10.1016/j.cell.2005.02.008.] [[PubMed][Google Scholar]
  • 13. Trojanowski J.Q., Lee V.M.YThe Alzheimer’s brain binding out what’s broken tells us how to fix it. Am J Pathol. 2005;167:1183–1188. doi: 10.1016/S0002-9440(10)61206-0.] [[Google Scholar]
  • 14. Armstrong R.AThe pathogenesis of Alzheimer’s disease: a reevaluation of the “amyloid cascade hypothesis” Int J Alzheimers Dis. 2011;2011:630865.[Google Scholar]
  • 15. Schwartz J.HAxonal transport: components, mechanisms, and specificity. Annu Rev Neurosci. 1979;2:467–504. doi: 10.1146/annurev.ne.02.030179.002343.] [[PubMed][Google Scholar]
  • 16. Hirokawa NKinesin and dynein superfamily proteins and the mechanism of organelle transport. Science. 1998;279:519–526. doi: 10.1126/science.279.5350.519.] [[PubMed][Google Scholar]
  • 17. Dai J., Buijs R.M., Kamphorst W., Swaab D.FImpaired axonal transport of cortical neurons in Alzheimer’s disease is associated with neuropathological changes. Brain Res. 2002;948:138–144. doi: 10.1016/S0006-8993(02)03152-9.] [[PubMed][Google Scholar]
  • 18. Dai J., Buijs R.M., Swaab D.FGlucocorticoid hormone (cortisol) affects axonal transport in human cortex neurons but shows resistance in Alzheimer’s disease. Br J Pharmacol. 2004;143:606–610. doi: 10.1038/sj.bjp.0705995.] [[Google Scholar]
  • 19. Stokin G.B., Lillo C., Falzone T.L., Brusch R.G., Rockenstein E., Mount S.L., et al Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease. Science. 2005;307:1282–1288. doi: 10.1126/science.1105681.] [[PubMed][Google Scholar]
  • 20. Stokin G.B., Goldstein L.SAxonal transport and Alzheimer’s disease. Annu Rev Biochem. 2006;75:607–627. doi: 10.1146/annurev.biochem.75.103004.142637.] [[PubMed][Google Scholar]
  • 21. Smith K.D., Kallhoff V., Zheng H., Pautler R.G. In vivo axonal transport rates decrease in a mouse model of Alzheimer’s disease. Neuroimage. 2007;35:1401–1408. doi: 10.1016/j.neuroimage.2007.01.046.] [
  • 22. Lazarov O., Morfini G.A., Pigino G., Gadadhar A., Chen X., Robinson J., et al Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer’s diseaselinked mutant presenilin 1. J Neurosci. 2007;27:7011–7020. doi: 10.1523/JNEUROSCI.4272-06.2007.] [[Google Scholar]
  • 23. Minoshima S., Cross D. In vivo imaging of axonal transport using MRI: aging and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2008;35(Suppl1):S89–92. doi: 10.1007/s00259-007-0707-8.] [[PubMed]
  • 24. Adalbert R., Nogradi A., Babetto E., Janeckova L., Walker S.A., Kerschensteiner M., et al Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. Brain. 2008;132:402–416. doi: 10.1093/brain/awn312.] [[PubMed][Google Scholar]
  • 25. Vickers J.C., King A.E., Woodhouse A., Kirkcaldie M.T., Staal J.A., McCormack G.H., et al Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system. Brain Res Bull. 2009;80:217–223. doi: 10.1016/j.brainresbull.2009.08.004.] [[PubMed][Google Scholar]
  • 26. Muresan V., Muresan ZIs abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimer’s disease? Future Neurol. 2009;4:761–773. doi: 10.2217/fnl.09.54.] [[Google Scholar]
  • 27. Massaad C.A., Amin S.K., Hu L., Mei Y., Klann E., Pautler R.GMitochondrial superoxide contributes to blood flow and axonal transport deficits in the Tg2576 mouse model of Alzheimer’s disease. PLoS One. 2010;5:e10561. doi: 10.1371/journal.pone.0010561.] [[Google Scholar]
  • 28. Xiao A., Dai JAxonal leakage is a key neuropathological change in Alzheimer’s disease. Acta Med Univ Sci Technol Huazhong. 2006;35:277–278.[PubMed][Google Scholar]
  • 29. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.MClinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34:939–944.[PubMed][Google Scholar]
  • 30. Braak H., Braak EDemonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991;1:213–216. doi: 10.1111/j.1750-3639.1991.tb00661.x.] [[PubMed][Google Scholar]
  • 31. Dai J., Swaab D.F., Van der Vliet J., Buijs R.MPostmortem tracing reveals the organization of hypothalamic projections of the suprachiasmatic nucleus in the human brain. J Comp Neurol. 1998;400:87–102. doi: 10.1002/(SICI)1096-9861(19981012)400:1<87::AID-CNE6>3.0.CO;2-P.] [[PubMed][Google Scholar]
  • 32. Erisir A., Aoki CA method of combining biocytin tract-tracing with avidin-biotin-peroxidase complex immunocytochemistry for pre-embedding electron microscopic labeling in neonatal tissue. J Neurosci Methods. 1998;81:189–197. doi: 10.1016/S0165-0270(98)00039-9.] [[PubMed][Google Scholar]
  • 33. Nunan J., Small D.HRegulation of APP cleavage by α-,β-, and γ -secretases. FEBS Lett. 2000;483:6–10. doi: 10.1016/S0014-5793(00)02076-7.] [[PubMed][Google Scholar]
  • 34. Shah S.B., Nolan R., Davis E., Stokin G.B., Niesman I., Canto I., et al Examination of potential mechanisms of amyloid-induced defects in neuronal transport. Neurobiol Dis. 2009;36:11–25. doi: 10.1016/j.nbd.2009.05.016.] [[PubMed][Google Scholar]
  • 35. Meyer-Luehmann M., Spires-Jones T.L., Prada C., Garcia-Alloza M., de Calignon A., Rozkalne A., et al Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease. Nature. 2008;415:720–725. doi: 10.1038/nature06616.] [[Google Scholar]
  • 36. Steiner B., Mandelkow E.M., Biernat J., Gustke N., Meyer H.E., Schmidt B., et al Phosphorylation of microtubule-associated protein tau: identification of the site for Ca2+-calmodulin dependent kinase and relationship with tau phosphorylation in Alzheimer tangles. EMBO J. 1990;9:3539–3544.[Google Scholar]
  • 37. Fleming L.M., Johnson G.VModulation of the phosphorylation state of tau in situ: the roles of calcium and cyclic AMP. Biochem J. 1995;309:41–47.[Google Scholar]
  • 38. Cras P., Kawai M., Lowery D., Gonzalez-DeWhitt P., Greenberg B., Perry GSenile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc Natl Acad Sci U S A. 1991;88:7552–7556. doi: 10.1073/pnas.88.17.7552.] [[Google Scholar]
  • 39. Rifenburg R.P., Perry GDystrophic neurites define diffuse as well as core-containing senile plaques in Alzheimer’s disease. Neurodegeneration. 1995;4:235–237.[PubMed][Google Scholar]
  • 40. Lin M.T., Beal M.FMitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787–795. doi: 10.1038/nature05292.] [[PubMed][Google Scholar]
  • 41. Muhammad S., Bierhaus A., Schwaninger MReactive oxygen species in diabetes-induced vascular damage, stroke, and Alzheimer’s disease. J Alzheimers Dis. 2009;16:775–785.[PubMed][Google Scholar]
  • 42. Salmina A.BNeuron-glia interactions as therapeutic targets in neurodegeneration. J Alzheimers Dis. 2009;16:485–502.[PubMed][Google Scholar]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.